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Clinical applications in brain science have progressed at a glacial pace when compared to other 
medical disciplines. Treatments for most neurodegenerative brain diseases are limited, and cure 
strategies remain underdeveloped. Pressure to improve clinical outcomes in the neurological 
sciences is exacerbated by an aging population at risk for degenerative brain diseases. Fortunately, 
technical advances in the field of neuroimaging offer new promise, with enhanced characteri-
zation of microstructural anatomy, network connectivity, and functional biomarkers of health 
and disease. Articles highlighted in this issue describe cutting-edge applications targeting these 
outcomes using diffusion tensor imaging, diffusion-based tractography, and positron emission 
tomography. Finally, the glymphatic system is reviewed as a target for future neuroimaging 
investigation in clinical populations such as those with Alzheimer’s disease. Integration of these 
methods with new advances in computational science will inform mechanisms of healthy and 
dysfunctional brain mechanisms and ideally lead to new targeted therapeutic interventions.
Key words: Neuroimaging; Alzheimer’s disease; Aging
 The human brain remains one of the most puz-
zling mysteries in the known universe. Encased in 
bone and vulnerable to slight homeostatic disruption, 
the brain is not easily examined by observational 
methods or invasive experimental procedures. Early 
perspectives of basic structure-function relationships 
were informed by clinical evaluation of individuals 
who had survived traumatic brain injury, such as Mr. 
Phineas Gage (3). However, the resulting models of 
brain organization and physiology were incomplete 
due to heterogeneity in lesion location and sever-
ity across individuals and limited capacity to mea-
sure the impact of focal lesions on larger networks 
described in histopathological studies. New technical 
insights were needed to bridge the science from his-
topathological bench work to in vivo examinations of 
complex human behavior. The requisite technology 
in brain science would not be available for nearly a 
century after the clinical description of Mr. Gage. 
 By contrast, progress in the prevention, diagnosis, 
and treatment of diseases peripheral to the central 
nervous system (CNS) progressed steadily over this 
time period, with more rapid advances after the mid-
1900s. Cardiovascular and cerebrovascular diseases 
previously known as fatal became manageable for 
many individuals with medications, surgery, and/or 
changes in lifestyle factors related to disease onset 
and progression (e.g., smoking, obesity). Similar 
breakthroughs in the prevention and treatment of 
other disease areas (e.g., diabetes) eclipsed the pace 
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of discovery in brain science. The discrepancy in 
treatment options for conditions above vs. below the 
neck contributed to a growing population of adults 
living longer lifespans, including a growing number 
of individuals with age-associated neurodegenerative 
diseases (8). The limited treatment options for the 
projected expansion of adults with neurodegenera-
tive diseases of the brain such as Alzheimer’s disease, 
growing healthcare costs, and increasing numbers of 
uninsured individuals all pointed towards an emerg-
ing health crisis. 
 Political pressure culminated in a Presidential 
proclamation signed in 1989 declaring the period 
from 1990-1999 as the “Decade of the Brain” (5). 
The initiative targeted 14 areas in the neurological 
sciences primed for breakthroughs in prevention, 
treatment, and cures for the most vexing and com-
mon neurological conditions. The Decade ended 
with few treatments and no interventions capable 
of reversing or halting common forms of neuro-
degenerative diseases, such as Alzheimer’s disease, 
Parkinson’s disease, or vascular dementia. However, 
innovative work in the field of neural bioinformatics 
and neuroimaging flourished during this period, and 
enthusiasm was high that neuroimaging technology 
seeded during the 1990s would significantly alter the 
cadence of brain science outcomes in the near future 
(10). This prediction proved accurate as borne out 
through subsequent research that leveraged a his-
torical foundation in magnetic resonance imaging 
(MRI). 
 Early MRI systems introduced in the 1970s pro-
vided researchers and clinicians with vastly improved 
spatial resolution of brain anatomy compared to 
radiographic methods of the past. High field MRI 
using 1.5 Tesla (15,000 Gauss) became common in 
both research and clinical settings, followed by the 
introduction of 3 Tesla systems. The image resolution 
of 3 Tesla MRI is approximately 16 times that of 1.5 
Tesla systems, allowing for significantly improved 
signal-to-noise ratio and improved anatomical detail. 
Eventually, 4 Tesla and even 7 Tesla systems were 
introduced at select research centers, the latter pro-
viding a magnetic field 140,000 times that of earth’s 
gravitational force. The improvements in image acqui-
sition at higher field strengths combined with robust 
post-processing algorithms improved visualization 
of both healthy and pathological brain tissue (11). 
 Anatomical detail provided by high field MRI 
opened a new world of brain structure-function rela-
tionships supported by the demarcation of tissue 
classification into cortical gray matter, subcortical 
white matter, and subcortical gray matter. Volumes 
of brain regions (e.g., frontal lobe) and specific nuclei 
(e.g., caudate nucleus) could be readily quantified 
and contrasted between patient groups and healthy 
controls or analyzed within groups to determine the 
degree of shared variance between brain volumes 
and measures of cognition, personality, or emotion. 
Landmark studies revealed reduced hippocampal 
volume in the earliest stages of Alzheimer’s disease (6), 
microvascular infarcts in subcortical white matter (2), 
as well as numerous other clinically relevant findings. 
However, the focus on specific nuclei and regional 
lobes belied the anatomical complexity of the brain 
previously characterized in histological studies. Work 
dating back to Golgi and Cajal (1) brilliantly revealed 
the multiplex architecture of neural networks using 
relatively crude methods in the 1800s, yet modern 
neuroimaging studies restricted analyses to focal 
brain regions. In effect, the field defaulted to a digi-
tized version of phrenology, ascribing complex and 
diverse human behaviors to isolated brain volumes. 
New technology was needed to measure brain net-
work integrity on a larger scale. 
 The introduction of diffusion tensor imaging 
(DTI) opened a new technical portal away from the 
hyper-focused regionalization of volumetric studies. 
DTI measures the rate and direction of water flow (i.e., 
hydrogen) in the brain, both of which are altered by 
neuronal damage (9). Common DTI outputs include 
scalar metrics of water diffusion, such as fractional 
anisotropy, mean diffusivity, axial diffusivity, and 
radial diffusivity (see Baker et al. in this issue for 
review). Refinement of DTI pulse sequences during 
the Decade of the Brain allowed researchers to visual-
ize network connections by measuring the curvature 
of the diffusion metrics along known anatomical fas-
ciculi. For the first time, the structural integrity of the 
brain (later referred to as the connectome) (12) could 
be defined. Subsequent studies developed methods 
to quantify the integrity of brain white matter tracts 
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identified using specialized processing methods 
for DTI outcomes. One such method, quantified 
fiber bundle length, is described in the current issue 
by Zhang. Compelling evidence demonstrates the 
sensitivity of quantified fiber bundle length to per-
turbations in cognition and to genetic risk alleles 
associated with reduced brain integrity (see Baker 
et al. in this issue). Technical improvements to DTI 
applications continue to develop, including advances 
in pulse sequences and post-processing data compu-
tations. In the current issue of this journal, Salminen 
et al. describe a method to improve the DTI signal 
by suppressing artifact generated by cerebrospinal 
fluid (CSF). Application of this CSF-suppression 
method offers improved anatomical precision of 
DTI-informed network models and more robust 
characterization of the scalar indices. 
 A notable limitation of both structural MRI and 
DTI is the absence of direct functional information 
about the brain. Functional information is most 
commonly derived from functional MRI (fMRI) 
or positron emission tomography (PET). fMRI was 
introduced in the early part of the Decade of the Brain 
at the Society for Magnetic Resonance in Medicine 
annual meeting in 1991. The fMRI signal is generated 
by changes in the blood deoxyhemoglobin concentra-
tion associated with cognitive activity completed by 
the individual while inside the MR unit. The spatial 
resolution of fMRI for cortical functions is quite good, 
but poor temporal resolution and high data process-
ing demands have restricted widespread adoption in 
clinical settings. 
 By contrast, PET has long been the workhorse of 
clinical functional brain imaging. PET is capable of 
detecting functional properties of the brain at the 
level of proteins or brain regions depending on the 
selection of isotopes or ligands. The degree of ana-
tomical specificity provided by PET represents an 
advantage over fMRI. Ligands are available for spe-
cific neurotransmitters (e.g., dopamine) and specific 
proteins, such as amyloid. In this issue, Cohen reviews 
the research and clinical relevance of Pittsburgh 
Compound-B (PiB), a PET ligand that selectively 
binds to the amyloid plaques characteristic of neu-
ropathology related to Alzheimer’s disease (13). PiB 
imaging is at the forefront of modern neuroimaging 
innovation, supported by evidence of abnormal PiB 
amyloid binding among older individuals at risk for 
future diagnosis of Alzheimer’s disease (reviewed by 
Cohen). 
 In addition to serving as markers of disease 
mechanisms, neuroimaging tools are sensitive to 
changes in brain integrity following treatment. Tate 
et al. review evidence of changes in PET, fMRI, and 
DTI indices following neuromodulation methods. 
PET imaging targeting the dopamine system reveals 
a potential mechanism of action of repetitive tran-
scranial magnetic stimulation, and DTI studies reveal 
improvement in fractional anisotropy in the brain 
ipsilateral to the treated hemisphere (as reviewed 
by Tate et al.). Additional randomized clinical trials 
are required to define the efficacy of neuromodula-
tion and the impact of treatment on brain network 
function, yet the innovative methods represent an 
intriguing non-pharmacological approach or adju-
vant treatment to maximize current pharmacological 
interventions. 
 This special issue of Technology and Innovation 
concludes with a contribution from Huffman et al. 
introducing a new frontier in imaging with high 
research and clinical relevance. The glymphatic 
and perivascular waste clearance systems identified 
recently in the brain have sparked both controversy 
and innovation (7). Once considered anatomically 
distinct from the periphery, the CNS is linked to 
the periphery through pathways that facilitate clear-
ance of waste products across the blood-brain-barrier 
(BBB) (7). As reviewed by Huffman et al., identifi-
cation of these pathways has opened a new world of 
discovery regarding communication between the 
CSF and plasma. Neuroimaging methods applied to 
animal models reveal waste products from metabolic 
functions and break-down of amyloid clear the CNS 
through these pathways, and, therefore, damage to 
this system may play a pivotal role in the pathogenesis 
of neurodegenerative diseases such as Alzheimer’s 
disease. Unfortunately, neuroimaging methods to 
examine this system are currently limited to ani-
mal studies. New innovation is required to translate 
these methods to human application and successfully 
define the relevance of disturbed glymphatic flow 
dynamics to human brain models. 
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 The primary governor of progress in brain sci-
ence is the extraordinary complexity of the brain. 
Comprised of a dizzying number of interconnections, 
the brain is estimated to include as many as 1011 x 1014 
synapses. Until recently, the computational methods 
required to capture the structural and functional com-
plexity of the human brain in vivo were non-existent. 
Neuroimaging technology now permits microscopic 
analyses and visualization of complete tracts and 
systems. Functional neuroimaging methods using 
biologically-specific ligands such as PiB reliably iden-
tify individuals at risk for developing dementia, with 
new advances coming from ligands for tau and other 
neuropathological markers of disease. Finally, it is 
likely that future models of brain structure-function 
will incorporate waste clearance dynamics occurring 
through central-peripheral exchange. Once estab-
lished, treatment (e.g., neuromodulation) and cure 
strategies can be strategically targeted against specific 
mechanisms of brain dysfunction. 
 Ambitious initiatives are underway to define the 
human brain connectome (12). Detailed mapping 
of brain circuitry provided from the connectome 
project will set a new water mark, with an emphasis 
on complete and integrated brain circuits. Delineation 
of brain phenotypes and endophenotypes will emerge 
from the integration of multiple imaging modalities, 
such as DTI/diffusion spectrum imaging and rest-
ing state fMRI. The neuroimaging field has already 
shifted in this new direction (4). The rich outcomes 
generated from these studies are critical to develop 
cost-effective options for personalized medicine 
and optimal patient outcomes. Undoubtedly, prog-
ress will be governed by the pace of innovation in 
computational science and federal funding for new 
research. A new political stage was set in April of 
2013, with President Obama announcing the launch 
of the BRAIN Initiative with coordinated funding 
from multiple federal sources to support interdisci-
plinary and highly integrated brain science research. 
Time will determine whether the new initiative is 
sufficiently funded to support the development of 
treatments that can arrest and/or reverse neurolog-
ical disease. There is little doubt, however, that the 
neuroimaging technology described in this issue will 
play a role in this next wave of strategic brain science 
aimed at improving the lives of individuals affected 
by a neurological illness worldwide. 
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